ATE442592T1 - Detektion und/oder beobachtung von synuclein- assoziierten krankheiten - Google Patents
Detektion und/oder beobachtung von synuclein- assoziierten krankheitenInfo
- Publication number
- ATE442592T1 ATE442592T1 AT03709934T AT03709934T ATE442592T1 AT E442592 T1 ATE442592 T1 AT E442592T1 AT 03709934 T AT03709934 T AT 03709934T AT 03709934 T AT03709934 T AT 03709934T AT E442592 T1 ATE442592 T1 AT E442592T1
- Authority
- AT
- Austria
- Prior art keywords
- synuclein
- monitoring
- detection
- patient
- associated diseases
- Prior art date
Links
- 238000012544 monitoring process Methods 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 102000019355 Synuclein Human genes 0.000 abstract 3
- 108050006783 Synuclein Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 208000032859 Synucleinopathies Diseases 0.000 abstract 2
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0203446.0A GB0203446D0 (en) | 2002-02-14 | 2002-02-14 | Detection and/or monitoring of synuclein-related diseases |
| PCT/GB2003/000677 WO2003069332A2 (en) | 2002-02-14 | 2003-02-14 | Detection and/or monitoring of synuclein-related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE442592T1 true ATE442592T1 (de) | 2009-09-15 |
Family
ID=9931023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03709934T ATE442592T1 (de) | 2002-02-14 | 2003-02-14 | Detektion und/oder beobachtung von synuclein- assoziierten krankheiten |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050176078A1 (de) |
| EP (1) | EP1476758B2 (de) |
| JP (1) | JP2005528588A (de) |
| AT (1) | ATE442592T1 (de) |
| AU (1) | AU2003214364A1 (de) |
| CA (1) | CA2480466C (de) |
| DE (1) | DE60329165D1 (de) |
| GB (1) | GB0203446D0 (de) |
| WO (1) | WO2003069332A2 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040146521A1 (en) * | 1999-06-01 | 2004-07-29 | Schenk Dale B. | Prevention and treatment of synucleinopathic disease |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| WO2005047860A2 (en) * | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| ES2310057B1 (es) * | 2004-07-19 | 2009-11-17 | Oryzon Genomics, S.A. | Metodo de analisis molecular y tratamiento en demencia de cuerpos de lewy. |
| CN1752104B (zh) * | 2004-09-21 | 2010-05-05 | 北京市肿瘤防治研究所 | 突触蛋白γ的单克隆抗体及其应用 |
| WO2007011907A2 (en) * | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
| US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| PL2583978T3 (pl) * | 2007-02-23 | 2016-07-29 | Prothena Biosciences Ltd Co | Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych |
| GB0716885D0 (en) | 2007-08-30 | 2007-10-10 | United Arab Emirates Universit | Diagnostic agent |
| WO2010069603A1 (en) | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| US20120190652A1 (en) * | 2009-09-16 | 2012-07-26 | United Arab Emirates University | Diagnostic agent for parkinson's disease |
| CN101692092B (zh) * | 2009-09-24 | 2013-04-10 | 首都医科大学宣武医院 | 定量检测人血清中自体α-突触核蛋白抗体的方法 |
| US11249092B2 (en) | 2017-05-16 | 2022-02-15 | Amprion, Inc. | Detection of misfolded tau protein |
| US10989718B2 (en) * | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
| US20130289022A1 (en) * | 2010-11-05 | 2013-10-31 | Brandeis University | Tetrameric alpha-synuclein and use thereof |
| WO2012061786A1 (en) * | 2010-11-05 | 2012-05-10 | Brandeis University | Ice cleaved alpha-synuclein a biomarker |
| AU2011336895A1 (en) * | 2010-11-24 | 2013-06-06 | Elan Pharmaceuticals, Inc. | Phagocytic activity as a marker of synucleinopathic disease |
| EP2723379B1 (de) | 2011-06-23 | 2018-09-12 | Biogen International Neuroscience GmbH | Anti-alpha-synuklein-bindende moleküle |
| CN107091931A (zh) * | 2011-11-02 | 2017-08-25 | 生物国际神经系统科学公司 | 抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途 |
| ES2481517B1 (es) * | 2013-01-29 | 2015-06-01 | Universidad De Sevilla | Método para el diagnóstico de la enfermedad de parkinson en estadios tempranos |
| WO2016040907A1 (en) * | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded proteins |
| EP4356967A3 (de) | 2014-11-14 | 2024-07-24 | United Arab Emirates University | Verbindungen zur verwendung als bildgebungsmittel |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN104711280B (zh) * | 2014-12-10 | 2018-04-13 | 中国医学科学院医学生物学研究所 | 表达和纯化同时缺失外显子3和5 的α突触核蛋白选择性剪切体蛋白的方法 |
| JP2020524667A (ja) * | 2017-06-19 | 2020-08-20 | カイノス・メディスン・インコーポレイテッドＫａｉｎｏｓ Ｍｅｄｉｃｉｎｅ， Ｉｎｃ． | アルファ−シヌクレインの調節因子 |
| ES2945165T3 (es) | 2017-08-22 | 2023-06-28 | Biogen Ma Inc | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides |
| JP7173532B2 (ja) * | 2018-08-28 | 2022-11-16 | 学校法人順天堂 | α－シヌクレイノパチーの診断 |
| RU2703430C1 (ru) * | 2018-12-13 | 2019-10-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия |
| EP3779448A1 (de) * | 2019-08-12 | 2021-02-17 | Baden-Württemberg Stiftung gGmbH | Neuartiger diagnostischer marker für die creutzfeldt-jakob-krankheit und morbus-alzheimer |
| WO2021170659A1 (en) * | 2020-02-25 | 2021-09-02 | Markus Otto | Diagnosing a disease associated with synaptic degeneration using an elisa for determining a beta-synuclein concentration in csf |
| EP4252243A2 (de) | 2020-11-30 | 2023-10-04 | Enigma Biointelligence, Inc. | Nichtinvasive beurteilung von morbus alzheimer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602042A (en) * | 1994-04-14 | 1997-02-11 | Cytyc Corporation | Method and apparatus for magnetically separating biological particles from a mixture |
| AU3117799A (en) * | 1998-03-30 | 1999-10-18 | Trustees Of The University Of Pennsylvania, The | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
| JP2002519702A (ja) * | 1998-07-03 | 2002-07-02 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 神経変性の分別診断 |
| CA2415179A1 (en) * | 2000-07-07 | 2002-01-17 | Panacea Pharmaceuticals, Inc. | Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| US20020150948A1 (en) * | 2000-11-03 | 2002-10-17 | Gerardo Castillo | Antibody PTI-HS7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease |
-
2002
- 2002-02-14 GB GBGB0203446.0A patent/GB0203446D0/en not_active Ceased
-
2003
- 2003-02-14 EP EP03709934.8A patent/EP1476758B2/de not_active Expired - Lifetime
- 2003-02-14 JP JP2003568402A patent/JP2005528588A/ja active Pending
- 2003-02-14 DE DE60329165T patent/DE60329165D1/de not_active Expired - Lifetime
- 2003-02-14 AU AU2003214364A patent/AU2003214364A1/en not_active Abandoned
- 2003-02-14 WO PCT/GB2003/000677 patent/WO2003069332A2/en active Application Filing
- 2003-02-14 AT AT03709934T patent/ATE442592T1/de not_active IP Right Cessation
- 2003-02-14 CA CA2480466A patent/CA2480466C/en not_active Expired - Fee Related
- 2003-02-14 US US10/503,416 patent/US20050176078A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60329165D1 (de) | 2009-10-22 |
| WO2003069332A2 (en) | 2003-08-21 |
| AU2003214364A1 (en) | 2003-09-04 |
| EP1476758B1 (de) | 2009-09-09 |
| WO2003069332A3 (en) | 2004-01-08 |
| GB0203446D0 (en) | 2002-04-03 |
| EP1476758B2 (de) | 2015-02-11 |
| EP1476758A2 (de) | 2004-11-17 |
| CA2480466A1 (en) | 2003-08-21 |
| JP2005528588A (ja) | 2005-09-22 |
| US20050176078A1 (en) | 2005-08-11 |
| CA2480466C (en) | 2010-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE442592T1 (de) | Detektion und/oder beobachtung von synuclein- assoziierten krankheiten | |
| DE60326214D1 (de) | Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten | |
| DE60331921D1 (de) | Diagnose und prävention der krebszellinvasion | |
| DE60312309D1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
| DE60108230D1 (de) | Vorrichtung für diagnose und behandlung von arrhytmien | |
| DE602004010407D1 (de) | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden | |
| CY1110503T1 (el) | Πενταμιδινη για θεραπεια καρκινου | |
| WO2003087831A3 (en) | Proteins involved in breast cancer | |
| EP1501531A4 (de) | Verfahren zur behandlung von angst und stimmungsstörungen bei älternen personen | |
| WO2006094068A3 (en) | Hdac inhibitors that promote brm expression and brm related diagnostics | |
| ATE552776T1 (de) | Verfahren und vorrichtung zur überwachung eines sedierten patienten | |
| ATE430935T1 (de) | Nachweis und behandlung von prostatakrebs | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| ATE520987T1 (de) | Verfahren zum nachweis und/oder screening zur überwachung eines kolorektalkrebs in einem individuum | |
| DE60327530D1 (de) | Plasma urotensin und menschliche herzerkrankung | |
| WO2006047475A3 (en) | Detection and analysis of ophthalmically-relevant fluorescent molecules | |
| ATE452395T1 (de) | Verfahren und vorrichtung zum kommunizieren mit beistehenden im fall eines katastrophalen persönlichen notfalls | |
| AU2003272189A8 (en) | Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents | |
| ATE393243T1 (de) | Diagnostisches verfahren der mastozytose | |
| ATE554790T1 (de) | Verfahren und zusammensetzungen zur diagnose von asthma | |
| WO2004034994A3 (en) | Methods and compositions for determining risk of treatment toxicity | |
| ATE397090T1 (de) | Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen | |
| AU2003299389A8 (en) | PRP detection method using an aminoglycoside antibiotic | |
| ATE546544T1 (de) | Verfahren zur diagnose und behandlung von lungenkrebs | |
| EP1492880A4 (de) | Ex-vivo-verfahren zur bestimmung der cetp-aktivität und der wirksamkeit der behandlung von herzerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |